Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, Bushweller JH.

Nat Struct Mol Biol. 2010 Jan;17(1):62-8. doi: 10.1038/nsmb.1714. Epub 2009 Dec 13.

2.

Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.

Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, Bushweller JH, Zeleznik-Le NJ.

J Biol Chem. 2013 Oct 11;288(41):29901-10. doi: 10.1074/jbc.M113.474858. Epub 2013 Aug 29.

3.

Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase.

Allen MD, Grummitt CG, Hilcenko C, Min SY, Tonkin LM, Johnson CM, Freund SM, Bycroft M, Warren AJ.

EMBO J. 2006 Oct 4;25(19):4503-12. Epub 2006 Sep 21.

5.

Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.

Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M, Zeleznik-Le NJ, Bushweller JH.

Cell Rep. 2015 May 5;11(5):808-20. doi: 10.1016/j.celrep.2015.04.004. Epub 2015 Apr 23.

6.

The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.

Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, Basrur V, Elenitoba-Johnson KS, Hess JL.

Cancer Cell. 2010 Jun 15;17(6):609-21. doi: 10.1016/j.ccr.2010.04.012.

7.

The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.

Murai MJ, Pollock J, He S, Miao H, Purohit T, Yokom A, Hess JL, Muntean AG, Grembecka J, Cierpicki T.

Blood. 2014 Dec 11;124(25):3730-7. doi: 10.1182/blood-2014-01-550079. Epub 2014 Oct 10.

8.

Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Shen C, Jo SY, Liao C, Hess JL, Nikolovska-Coleska Z.

J Biol Chem. 2013 Oct 18;288(42):30585-96. doi: 10.1074/jbc.M113.457135. Epub 2013 Sep 1.

9.

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.

Nguyen AT, Taranova O, He J, Zhang Y.

Blood. 2011 Jun 23;117(25):6912-22. doi: 10.1182/blood-2011-02-334359. Epub 2011 Apr 26.

10.

Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.

Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK.

Oncogene. 2009 Feb 12;28(6):815-23. doi: 10.1038/onc.2008.443. Epub 2008 Dec 8.

PMID:
19060922
11.

MLL targets SET domain methyltransferase activity to Hox gene promoters.

Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL.

Mol Cell. 2002 Nov;10(5):1107-17.

12.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

13.

Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, Gozani O, Kutateladze TG, Cleary ML.

J Mol Biol. 2010 Jul 9;400(2):137-44. doi: 10.1016/j.jmb.2010.05.005. Epub 2010 May 7.

14.

MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, Zhang H, Liu Z, Ernst P, Koretzky GA, Hua X.

Cancer Cell. 2010 Feb 17;17(2):148-59. doi: 10.1016/j.ccr.2009.12.034.

15.

Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.

Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KS, Allis CD, Roeder RG.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15751-6. doi: 10.1073/pnas.1111498108. Epub 2011 Sep 6.

16.

Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.

Cermáková K, Tesina P, Demeulemeester J, El Ashkar S, Méreau H, Schwaller J, Rezáčová P, Veverka V, De Rijck J.

Cancer Res. 2014 Sep 15;74(18):5139-51. doi: 10.1158/0008-5472.CAN-13-3602. Epub 2014 Jul 31.

17.

Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.

Zhang Y, Owens K, Hatem L, Glass CH, Karuppaiah K, Camargo F, Perkins AS.

Blood. 2013 Oct 17;122(16):2888-92. doi: 10.1182/blood-2012-08-453662. Epub 2013 Sep 10.

18.

c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.

Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM.

J Clin Invest. 2010 Feb;120(2):593-606. doi: 10.1172/JCI38030. Epub 2010 Jan 19.

19.

Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.

Grembecka J, Belcher AM, Hartley T, Cierpicki T.

J Biol Chem. 2010 Dec 24;285(52):40690-8. doi: 10.1074/jbc.M110.172783. Epub 2010 Oct 20.

20.

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA.

Leukemia. 2008 Jan;22(1):66-77. Epub 2007 Sep 13.

Supplemental Content

Support Center